DETECTION IN CLINICAL PRACTICE

ADmit Therapeutics, S.L. is a company focused on the development and commercialization of a novel Alzheimer's disease (AD) early detection technology.

RigurosityOur clinical studies are rigurously analyzed

EfficiencyWe optimize our own resources Agility

AgilityWe adopt agile decissions

TEAMWORK AND INNOVATION

Our technology represents the determination of biomarkers non-related with β-amyloid nor tau.

Our findings may become a pool of biomarkers very useful for the detection of patients at early stages of AD.

News

ADmit therapeutics closes a €5.4 million funding round led by Clave Capital, through its Clave Innohealth f.c.r. fund The European Innovation Council (EIC) Fund and the Alzheimer's Drug Discovery Foundation (ADDF) Diagnostic Accelerator (DxA) join the ro
ADmit has secured a €5.4 million equity round with Clave Capital as the lead investor, with significant support from the EIC Fund and the Alzheimer's Drug Discovery Foundation (ADDF) Diagnostics Accelerator (DxA), alongside other investors such as Lavanda Ventures, Ship2B and WA4Steam. ...

read more

OUR TEAM

Marta BarrachinaCEO
CO-FOUNDER
Chairman of the Board of Directors

Giacomo de SimoneMember of the Board of Directors

Maite FiblaMember of the Board of Directors

Tweets by ADmitTherapeut1

This website uses our own cookies and third-party cookies to collect information, in order to improve our services. Your continued use of this website constitutes acceptance of the installation of these cookies. The user has the option of configuring their browser in order to prevent cookies from being installed on their hard drive, although they must keep in mind that doing so may cause difficulties in their use of the webpage. I Agree How to configure browser